SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates a potential rally, with some suggesting the possibility of new all-time highs. Speculation around upcoming ETFs and large purchases from Dogecoin treasury companies are being discussed as potential catalysts. Traders are closely watching key price levels and anticipating significant movement in the near future.

The Open Crypto Foundation (OCF) represents a paradigm shift in the blockchain ecosystem, establishing a robust framework for secure, transparent, and interoperable decentralized applications. Our mission encompasses the development of cutting-edge cryptographic solutions, the implementation of advanced consensus mechanisms, and the creation of a comprehensive ecosystem that prioritizes security, scalability, and user sovereignty.  Through our subsidiary OpenLabs, we are pioneering the OpenNet blockchain protocol, a next-generation distributed ledger technology that integrates zero-knowledge proofs, sharding mechanisms, and cross-chain interoperability protocols to deliver unprecedented performance and security guarantees.  The token economics of OpenNet are designed to create a synergistic relationship between utility, security, and decentralized governance. The open token fuels network activity and application usage, while the stake token secures the network through PoS and empowers the community DAO. The initial allocation provides a foundation, but the long-term evolution of supply, rewards, and resource allocation is placed firmly in the hands of the stake holders.

WOPEN

WOPEN.X is trending as community members highlight its low market cap and potential for significant growth, calling it an "early entry play." There is a sense of urgency to accumulate before a potential breakout, with many referring to it as a "sleeping giant" ready to "moonshot." The token is associated with the Solana ecosystem.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies behind its fair distribution and strong community, emphasizing its position as a top meme coin on the Bitcoin network. Discussions highlight its unique status as a meme coin built on Bitcoin's Runes protocol, contrasting it with other meme coins and promoting its potential for significant growth. The community emphasizes its organic nature, lack of insiders, and strong holder base as key factors driving its popularity.

Spell Token

Spell Token is trending as the community anticipates a potential surge, with some mentioning targets like "pennyland" and others expressing frustration over its price movement. Discussions also include speculation about factors such as coin dilution and potential catalysts. Some users are comparing it to other tokens and suggesting it as a potential pump and dump.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as it experiences significant price movement, with the community discussing its potential to reach higher valuations. Some users are drawing comparisons to other tokens, while highlighting its fundamentals, such as being a perpetuals exchange on the Base network backed by Pantera Capital. The conversation also includes speculation around future developments, like trading RWA assets.

Pump.fun

$PUMP.X is gaining traction as a launchpad for new meme coins on the Solana network, with the community actively discussing potential gains and strategies. Some members highlight the ecosystem's revenue-sharing model with its community, while others are focusing on technical analysis and short-term trading opportunities. The coin is also generating buzz as a potential alternative within the broader meme coin landscape.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential to reach new price levels and its growing ecosystem. Some are pointing to institutional interest and accumulation as a driver, while others highlight its growing use cases in payments and mobile applications. The conversation also includes discussion of Solana-based meme coins and treasury plays.

BlackBerry Ltd

BlackBerry ($BB.TSX) is trending as investors discuss its potential, particularly around its QNX technology and potential deals, and whether a low valuation represents a buying opportunity. Community members highlight QNX's presence in various industries, including automotive and robotics, with some drawing attention to a growing sales pipeline.  Some investors are also speculating about potential strategic moves and what they might mean for the company's future.

Ainalyzr is a versatile and engaging platform designed to provide crypto traders with advanced tools and a fun, interactive environment. Powered by the Ainalyzr token, it offers real-time analysis of Solana-based tokens, gamified trading tools, and a space for users to explore market trends and make data-driven decisions. Ainalyzr merges functionality and entertainment, appealing to both seasoned and novice traders.

AInalyzr

AInalyzr ($AINAL.X) is trending as the crypto community discusses its potential for a significant pump, with many referencing a "rocket" or "moonshot." Community members highlight the opportunity for early entry and substantial gains, while some express caution due to its volatile nature. Discussions also point to the coin's activity on Solana-based platforms.

"What's Updog?" is a Community Led token.

UpDog

UpDog ($UPDOG.X) is trending as the community rallies behind its charitable donations to dog shelters, a unique aspect for a meme coin. Many are drawn to its mission, highlighting its potential for significant growth within the Solana ecosystem alongside other dog-themed tokens like $DOGE.X and $SHIB.X. The project's presence on Jupiter Strict List is also contributing to its visibility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pacira (PCRX) Tops Q2 Earnings Estimates

Pacira (PCRX) delivered earnings and revenue surprises of +2.78% and -1.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Pacira BioSciences Inc (PCRX) traded 19% higher on Tuesday morning, following upward price target revisions by multiple brokerages following a patent litigation settlement.Pacira <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.pacira.com/news-releases/news-release-details/pacira-biosciences-announces-settlement-us-patent-litigation">announced</a> on Monday that it has settled its litigations related to patents for EXPAREL or bupivacaine liposome injectable suspension, a long-acting local pain reliever.As part of the settlement, Pacira agreed to provide Fresenius Kabi USA, LLC with a license to Pacira’s patents required to manufacture and sell certain volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date sometime in early 2030.Pacira also agreed to provide Fresenius with a license to Pacira’s patents required to manufacture and sell an unlimited quantity of generic bupivacaine liposome injectable suspension in the U.S. beginning no earlier than 2039.Pacira CEO Frank D. Lee said Monday that the settlement agreement provides “clarity” around EXPAREL exclusivity.Meanwhile, H.C. Wainwright raised the firm's price target on Pacira to $65 from $48 while keeping a ‘Buy’ rating on the shares.The firm opined that the Street is "wildly overestimating" the company's Exparel generic risk and "dramatically underpricing" Pacira shares, according to TheFly.RBC Capital also raised its price target on Pacira to $26 from $22 on Tuesday and maintained a “Sector Perform” rating on the shares.Pacira BioSciences’ settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise, the analyst said.It brings needed clarity and five years of protection to potentially realize the benefits of internal drivers, the analyst told investors in a research note.Truist also raised its price target on Pacira to $28 from $25 and kept a ‘Hold’ rating on the shares. The firm now envisions peak Exparel sales of $740 million by 2029.On Stocktwits, retail sentiment about PCRX jumped from ‘extremely bearish’ to ‘extremely bullish’ territory while message volume jumped from ‘high’ to ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:650/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_08_at_10_20_15_AM_png_84a9d54519.webp" alt="PCRX's Sentiment Meter and Message Volume as of 10:20 a.m. ET on April 8, 2025 | Source: Stocktwits" width="650" height="150"><figcaption>PCRX's Sentiment Meter and Message Volume as of 10:20 a.m. ET on April 8, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/PCRX">PCRX Shares</a> have risen nearly 49% this year but have fallen over 4% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cvs-health-appoints-new-cfo-chief-medical-officer/chflzodRbJf">CVS Health Appoints New CFO, Chief Medical Officer: Retail Sentiment Soars</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Pacira Biosciences Stock Rises On Multiple Price Target Upgrades: Retail Sentiment Soars

RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise.

Equity

Shares of Pacira BioSciences Inc. soared over 22% in extended trading on Monday after the company said it had resolved a legal case over its long-acting pain medication.&nbsp;Pacira has settled litigation with Germany's Fresenius Kabi and its partners over patents related to Exparel, which reportedly provides&nbsp;pain&nbsp;relief for up to 72 hours after surgery.As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030, when it will be allowed limited entry into the U.S. market under a confidential volume cap.The licensed volumes will start in the high single-digit percentage range and gradually increase each year, reaching the high thirty percent by the agreement's final years.&nbsp;Still, Fresenius will be permitted to sell unlimited volumes of its generic version starting in 2039, before Pacira's last-listed Exparel patent expires in July 2044.&nbsp;On Stocktwits, sentiment for Pacira jumped into ‘extremely bullish’ levels late Monday, accompanied by a 50% jump in message volume over the last 24 hours.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/PCRX_sentiment_and_message_volume_as_of_April_7_png_47dd0566cd.webp" alt="PCRX sentiment and message volume as of April 7.png" width="1318" height="316"><figcaption>PCRX sentiment and message volume as of April 7. | source: Stocktwits</figcaption></figure>"The settlement terms are notably favorable for Pacira. They've secured full exclusivity until early 2030 - providing at least 5 more years of uncontested market presence," said one user.<stembedurl>https://stocktwits.com/GoldKing23/message/610799845</stembedurl>"Market hates uncertainty—this clears the deck," posted another.<stembedurl>https://stocktwits.com/Rage_Against_The_Machine/message/610799401</stembedurl>In December 2024, Pacira was granted a U.S. Patent covering the chemical composition of Exparel.That same month, the company filed a lawsuit in Illinois to defend Exparel against generic challengers.<a href="https://stocktwits.com/symbol/PCRX">Pacira’s stock</a> has gained more than 20% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice

As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030.

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud...

Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline

Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of...

Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX

Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX Pacira BioSciences, Inc...

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit PR Newswire NEW...

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX PACIRA...

Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX

Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact...

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

PCRX
Pacira BioSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PCRX News

PCRX Pacira BioSciences Inc